Literature DB >> 16257561

Preparing for phase II/III HIV vaccine trials in Africa.

Eftyhia Vardas1, Stefano Buttò, Richard Glashoff, Mauro S Malnati, Guido Poli, Mario Clerici.   

Abstract

Before performing phase II/III clinical trials in Africa, preliminary studies, including assessment and building up of clinical and laboratory infrastructures, estimates of human immunodeficiency virus incidence, investigation of the background immune response, and evaluation of the cross-clade immune response, need to be done. Plans and ongoing work in the context of the AIDS Vaccine Integrated Project and some preliminary data are presented.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16257561     DOI： 10.1016/j.micinf.2005.07.021

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  5 in total

Review 1.  The potential role of biomarkers in HIV preventive vaccine trials.

Authors:  Ellen Maclachlan; Kenneth H Mayer; Ruanne Barnabas; Jorge Sanchez; Beryl Koblin; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

2.  Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection.

Authors:  Mauro Malnati; Antonio Cosma; Claudia J Dembek; Sarah Kutscher; Silvia Heltai; Simone Allgayer; Priscilla Biswas; Silvia Ghezzi; Elisa Vicenzi; Dieter Hoffmann; Peter Reitmeir; Giuseppe Tambussi; Johannes R Bogner; Paolo Lusso; Hans-J Stellbrink; Elena Santagostino; Thomas Vollbrecht; Frank D Goebel; Ulrike Protzer; Rika Draenert; Marco Tinelli; Guido Poli; Volker Erfle
Journal:  AIDS Res Ther       Date:  2010-07-02       Impact factor: 2.250

3.  Prevalence and incidence of HIV in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda.

Authors:  Eugene Ruzagira; Symon Wandiembe; Andrew Abaasa; Jonathan Levin; Agnes Bwanika; Ubaldo Bahemuka; Matthew A Price; Anatoli Kamali
Journal:  PLoS One       Date:  2011-06-03       Impact factor: 3.240

4.  Feasibility of establishing an HIV vaccine preparedness cohort in a population of the Uganda Police Force: Lessons learnt from a prospective study.

Authors:  Ubaldo Mushabe Bahemuka; Andrew Abaasa; Janet Seeley; Moses Byaruhanga; Anatoli Kamali; Philippe Mayaud; Monica Kuteesa
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

5.  The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

Authors:  Sarah Kutscher; Claudia J Dembek; Simone Allgayer; Silvia Heltai; Birgit Stadlbauer; Priscilla Biswas; Silvia Nozza; Giuseppe Tambussi; Johannes R Bogner; Hans J Stellbrink; Frank D Goebel; Paolo Lusso; Marco Tinelli; Guido Poli; Volker Erfle; Heike Pohla; Mauro Malnati; Antonio Cosma
Journal:  AIDS Res Ther       Date:  2008-10-06       Impact factor: 2.250
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.